These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 22612526

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH.
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ.
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B.
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [Abstract] [Full Text] [Related]

  • 6. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, McBurnett K, White C, Youcha S.
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
    [Abstract] [Full Text] [Related]

  • 7. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Huss M, McBurnett K, Cutler AJ, Hervás A, Bliss C, Gao J, Dirks B, Newcorn JH.
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):432-443. PubMed ID: 30064718
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study.
    Naya N, Sakai C, Okutsu D, Kiguchi R, Fujiwara M, Tsuji T, Iwanami A.
    Neuropsychopharmacol Rep; 2021 Mar; 41(1):26-39. PubMed ID: 33305542
    [Abstract] [Full Text] [Related]

  • 11. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH, López FA, Vince BD, Turnbow JM, Farrand K, Lyne A, Wigal SB, Roth T.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [Abstract] [Full Text] [Related]

  • 12. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
    Connor DF, Findling RL, Kollins SH, Sallee F, López FA, Lyne A, Tremblay G.
    CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.
    Pharmacoeconomics; 2012 Aug 01; 30(8):e1-15. PubMed ID: 22788263
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder.
    Newcorn JH, Huss M, Connor DF, Hervás A, Werner-Kiechle T, Robertson B.
    J Dev Behav Pediatr; 2020 Sep 01; 41(7):565-570. PubMed ID: 32482970
    [Abstract] [Full Text] [Related]

  • 18. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, SPD503 STUDY GROUP.
    J Am Acad Child Adolesc Psychiatry; 2009 Feb 01; 48(2):155-65. PubMed ID: 19106767
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ, Brams M, Bukstein O, Mattingly G, McBurnett K, White C, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2014 Oct 01; 53(10):1092-101. PubMed ID: 25245353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.